Brokerages Set Vor Biopharma Inc. (NYSE:VOR) PT at $11.36

Shares of Vor Biopharma Inc. (NYSE:VOR) have received a consensus recommendation of “Buy” from the seven analysts that are currently covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have issued a report on the stock in the last year is $11.36.

VOR has been the topic of a number of recent analyst reports. Robert W. Baird lowered their target price on shares of Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. HC Wainwright reissued a “buy” rating and issued a $17.50 price objective on shares of Vor Biopharma in a research report on Tuesday, December 10th. JMP Securities reissued a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research report on Tuesday, December 10th. Finally, Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Vor Biopharma in a research report on Monday, December 9th.

Institutional Trading of Vor Biopharma

Hedge funds have recently modified their holdings of the stock. Virtu Financial LLC bought a new stake in shares of Vor Biopharma during the fourth quarter worth approximately $60,000. Rosalind Advisors Inc. acquired a new position in Vor Biopharma in the 3rd quarter valued at $54,000. Exchange Traded Concepts LLC grew its holdings in Vor Biopharma by 40.8% in the 3rd quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock valued at $116,000 after buying an additional 48,017 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in Vor Biopharma in the 2nd quarter valued at $53,000. Finally, Renaissance Technologies LLC grew its holdings in Vor Biopharma by 48.0% in the 2nd quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock valued at $495,000 after buying an additional 160,642 shares in the last quarter. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Stock Down 3.6 %

VOR stock opened at $1.33 on Wednesday. The company has a market cap of $91.33 million, a price-to-earnings ratio of -0.81 and a beta of -0.45. Vor Biopharma has a twelve month low of $0.63 and a twelve month high of $2.43. The business has a 50 day moving average price of $1.23 and a two-hundred day moving average price of $0.97.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.